RT Journal Article
SR Electronic
T1 Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.02.15.24302857
DO 10.1101/2024.02.15.24302857
A1 Falk, August Jernbom
A1 Skoglund, Lovisa
A1 Pin, Elisa
A1 Sjöberg, Ronald
A1 Tegel, Hanna
A1 Hober, Sophia
A1 Rostami, Elham
A1 Rasmusson, Annica
A1 Cunningham, Janet L.
A1 Havervall, Sebastian
A1 Thålin, Charlotte
A1 Månberg, Anna
A1 Nilsson, Peter
YR 2024
UL http://medrxiv.org/content/early/2024/02/15/2024.02.15.24302857.abstract
AB Autoantibodies have been shown to be implied in COVID-19 but the emerging autoantibody repertoire remains largely unexplored. We investigated the new-onset autoantibody repertoire in 525 healthcare workers and hospitalized COVID-19 patients in five time points over 16 months using proteome-wide and targeted protein and peptide arrays. Our results show that prevalent new-onset autoantibodies against a wide range of antigens emerged following SARS-CoV-2 infection in relation to pre-infectious baseline samples and remained elevated for at least 12 months. We demonstrated associations between distinct new-onset autoantibodies and neuropsychiatric symptoms post-COVID-19. Using epitope mapping, we determined the main epitopes of selected new-onset autoantibodies, validated them in independent cohorts of neuro-COVID and pre-pandemic healthy controls, and identified molecular mimicry between main epitopes and the conserved fusion peptide of the SARS-CoV-2 Spike glycoprotein. Our work describes the complexity and dynamics of the autoantibody repertoire emerging with COVID-19 and supports the need for continued analysis of the new-onset autoantibody repertoire to elucidate the mechanisms of the post-COVID-19 condition.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by a grant from the Swedish Research Council.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Swedish Ethical Review Authority gave ethical approval for this work under approval numbers: 2020-01653; 2021-04113; 2017-043 with amendments 2019-00169, 2020-01623, 2020-02719, 2020-05730, 2021-01469, and 2020-01883; 2014/148; and 2022-00526-01.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors and approval by the relevant ethical boards. Data cannot be shared freely as it contains sensitive personal data covered by the GDPR.